{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:56:52Z","timestamp":1789070212759,"version":"build-2803163510"},"reference-count":184,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Cardiovascular diseases cause considerable health and economic burden, as they are the leading\ncause of disability and death in the western world. Inactivity, hypertension, obesity, diabetes, and\nsmoking are among the classic risk factors for cardiovascular disease. From a pathophysiological point\nof view, the arteries of our body bear the harmful stimuli produced by these factors and respond to them\nwith a series of intricate adaptive mechanisms. Vascular remodeling constitutes an adaptive response to\nhemodynamic and inflammatory alterations associated with hypertension, diabetes, and other illnesses.\nThickening of the arterial walls leads to endothelial dysfunction and increases the risk of cerebrovascular\nand coronary events. During the last decades, antiplatelet, lipid-lowering, and antihypertensive\ntherapies have been the cornerstone of primary and secondary prevention of cardiovascular events.\nHowever, it is still unknown whether their efficacy is strictly associated with the control of the classical\nrisk factors or their additive effects on vascular inflammation. Since inflammation of arterial walls is\nrelated to the pathogenesis of atherosclerosis, it has been hypothesized that anti-inflammatory therapies\ncould prevent and treat vascular remodeling. Clinical trials based on canakinumab or hydroxychloroquine\nprovide further insight into the role of inflammation in the pathophysiology of cardiovascular\ndiseases. In this review, we have analyzed evidence and suggested that inflammation may play an important\nrole in the final pathway of many cardiovascular risk factors.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570161120666220201160038","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T04:24:03Z","timestamp":1643775843000},"page":"244-259","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Role of Inflammation as a Preponderant Risk Factor in Cardiovascular\nDiseases"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6654-214X","authenticated-orcid":true,"given":"Rodrigo Dami\u00e1n","family":"Garc\u00eda","sequence":"first","affiliation":[{"name":"Facultad de Ciencias M\u00e9dicas, Universidad Nacional de Cuyo, Mendoza, Argentina"},{"name":"Instituto de Medicina y Biolog\u00eda Experimental de Cuyo (IMBECU), CONICET, Mendoza, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3609-5593","authenticated-orcid":true,"given":"Joana Antonela","family":"Asensio","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias M\u00e9dicas, Universidad Nacional de Cuyo, Mendoza, Argentina"},{"name":"Instituto de Histolog\u00eda y Embriolog\u00eda de Mendoza (IHEM),\nCONICET, Mendoza, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6837-3581","authenticated-orcid":true,"given":"Diahann Jeanette","family":"Perdicaro","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias M\u00e9dicas, Universidad Nacional de Cuyo, Mendoza, Argentina"},{"name":"Instituto de Medicina y Biolog\u00eda Experimental de Cuyo (IMBECU), CONICET, Mendoza, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"de los \u00c1ngeles Peral","sequence":"additional","affiliation":[{"name":"Instituto Superior De Investigaciones Biol\u00f3gicas (INSIBIO), CONICET, Tucum\u00e1n, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"World Health Organization. Cardiovascular diseases (CVDs) 2021."},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","volume":"7","author":"Kaptoge S.","year":"2019","unstructured":"Kaptoge S.; Pennells L.; De Bacquer D.; World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health 2019,7(10),e1332-e1345","journal-title":"Lancet Glob Health"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"Roth G.A.","year":"2020","unstructured":"Roth G.A.; Mensah G.A.; Johnson C.O.; Global burden of cardiovascular diseases and risk factors, 1990-2019. J Am Coll Cardiol 2020,76(25),2982-3021","journal-title":"J Am Coll Cardiol"},{"key":"ref=4","author":"Bloom D.E.","unstructured":"Bloom D.E.; Cafiero E.T.; Jan\u00e9-Llopis E.;  The global economic burden of noncommunicable diseases. Geneva: World Economic Forum, 2011."},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.7326\/0003-4819-55-1-33","volume":"55","author":"Kannel W.B.","year":"1961","unstructured":"Kannel W.B.; Dawber T.R.; Kagan A.; Revotskie N.; Stokes J.; Factors of risk in the development of coronary heart disease--six year fol-low-up experience. The Framingham Study. Ann Intern Med 1961,55(1),33-50","journal-title":"Ann Intern Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41569-019-0202-5","volume":"16","author":"Andersson C.","year":"2019","unstructured":"Andersson C.; Johnson A.D.; Benjamin E.J.; Levy D.; Vasan R.S.; 70-year legacy of the Framingham Heart Study. Nat Rev Cardiol 2019,16(11),687-698","journal-title":"Nat Rev Cardiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1157\/13116658","volume":"61","author":"O\u2019Donnell C.J.","year":"2008","unstructured":"O\u2019Donnell C.J.; Elosua R.; Cardiovascular risk factors. Insights from Framingham Heart Study. Rev Esp Cardiol 2008,61(3),299-310","journal-title":"Rev Esp Cardiol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"Virani S.S.","year":"2021","unstructured":"Virani S.S.; Alonso A.; Aparicio H.J.; Heart disease and stroke statistics-2021 update: A report from the american heart association. Circulation 2021,143(8),e254-e743","journal-title":"Circulation"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1067\/mhj.2001.109951","volume":"141","author":"Wood D.","year":"2001","unstructured":"Wood D.; Established and emerging cardiovascular risk factors. Am Heart J 2001,141(2)(Suppl.),S49-S57","journal-title":"Am Heart J"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"Unger T.","year":"2020","unstructured":"Unger T.; Borghi C.; Charchar F.; International society of hypertension global hypertension practice guidelines. Hypertension 2020,75(6),1334-1357","journal-title":"Hypertension"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jama.2016.19043","volume":"317","author":"Forouzanfar M.H.","year":"2017","unstructured":"Forouzanfar M.H.; Liu P.; Roth G.A.; Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA 2017,317(2),165-182","journal-title":"JAMA"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1093\/ajh\/hpaa195","volume":"34","author":"Humphrey J.D.","year":"2021","unstructured":"Humphrey J.D.; Mechanisms of vascular remodeling in hypertension. Am J Hypertens 2021,34(5),432-441","journal-title":"Am J Hypertens"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"A11913069","DOI":"10.1161\/HYPERTENSIONAHA.119.13069","volume":"74","author":"Suvila K.","year":"2019","unstructured":"Suvila K.; McCabe E.L.; Lehtonen A.; Early onset hypertension is associated with hypertensive end-organ damage ALREADY by MIDLIFE. Hypertension 2019,74(2),A11913069","journal-title":"Hypertension"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1016\/j.jacc.2020.04.038","volume":"75","author":"Wang C.","year":"2020","unstructured":"Wang C.; Yuan Y.; Zheng M.; Association of age of onset of hypertension with cardiovascular diseases and mortality. J Am Coll Cardiol 2020,75(23),2921-2930","journal-title":"J Am Coll Cardiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"4478","DOI":"10.1073\/pnas.071052598","volume":"98","author":"Garcia-Carde\u00f1a G.","year":"2001","unstructured":"Garcia-Carde\u00f1a G.; Comander J.; Anderson K.R.; Blackman B.R.; Gimbrone M.A.; Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci USA 2001,98(8),4478-4485","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=16","first-page":"9","volume":"46","author":"Papaioannou T.G.","year":"2005","unstructured":"Papaioannou T.G.; Stefanadis C.; Vascular wall shear stress: Basic principles and methods. Hellenic J Cardiol 2005,46(1),9-15","journal-title":"Hellenic J Cardiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/325811a0","volume":"325","author":"Lansman J.B.","year":"1987","unstructured":"Lansman J.B.; Hallam T.J.; Rink T.J.; Single stretch-activated ion channels in vascular endothelial cells as mechanotransducers? Nature 1987,325(6107),811-813","journal-title":"Nature"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/288373a0","volume":"288","author":"Furchgott R.F.","year":"1980","unstructured":"Furchgott R.F.; Zawadzki J.V.; The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980,288(5789),373-376","journal-title":"Nature"},{"key":"ref=19","author":"Rubanyi G.M.","year":"1999","unstructured":"Rubanyi G.M.;  Pathophysiology and Clinical Applications of Nitric Oxide 1999","journal-title":"Pathophysiology and Clinical Applications of Nitric Oxide"},{"key":"ref=20","first-page":"405","volume":"103","author":"Vanhoutte P.M.","year":"1991","unstructured":"Vanhoutte P.M.; Eber B.; Endothelium-derived relaxing and contracting factors. Wien Klin Wochenschr 1991,103(14),405-411","journal-title":"Wien Klin Wochenschr"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1159\/000339151","volume":"49","author":"Anwar M.A.","year":"2012","unstructured":"Anwar M.A.; Shalhoub J.; Lim C.S.; Gohel M.S.; Davies A.H.; The effect of pressure-induced mechanical stretch on vascular wall differential gene expression. J Vasc Res 2012,49(6),463-478","journal-title":"J Vasc Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"599415","DOI":"10.3389\/fimmu.2020.599415","volume":"11","author":"Sorokin V.","year":"2020","unstructured":"Sorokin V.; Vickneson K.; Kofidis T.; Role of vascular smooth muscle cell plasticity and interactions in vessel wall inflammation. Front Immunol 2020,11,599415","journal-title":"Front Immunol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/hr.2010.187","volume":"33","author":"Liu G.","year":"2010","unstructured":"Liu G.; Hitomi H.; Hosomi N.; Mechanical stretch potentiates angiotensin II-induced proliferation in spontaneously hypertensive rat vascular smooth muscle cells. Hypertens Res 2010,33(12),1250-1257","journal-title":"Hypertens Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/cvr\/cvs135","volume":"95","author":"Lacolley P.","year":"2012","unstructured":"Lacolley P.; Regnault V.; Nicoletti A.; Li Z.; Michel J.B.; The vascular smooth muscle cell in arterial pathology: A cell that can take on multiple roles. Cardiovasc Res 2012,95(2),194-204","journal-title":"Cardiovasc Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-2796.2006.01624.x","volume":"259","author":"Lehoux S.","year":"2006","unstructured":"Lehoux S.; Castier Y.; Tedgui A.; Molecular mechanisms of the vascular responses to haemodynamic forces. J Intern Med 2006,259(4),381-392","journal-title":"J Intern Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"C481","DOI":"10.1152\/ajpcell.00147.2020","volume":"319","author":"Ma Z.","year":"2020","unstructured":"Ma Z.; Mao C.; Jia Y.; Fu Y.; Kong W.; Extracellular matrix dynamics in vascular remodeling. Am J Physiol Cell Physiol 2020,319(3),C481-C499","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1161\/01.HYP.38.3.399","volume":"38","author":"Chae C.U.","year":"2001","unstructured":"Chae C.U.; Lee R.T.; Rifai N.; Ridker P.M.; Blood pressure and inflammation in apparently healthy men. Hypertension 2001,38(3),399-403","journal-title":"Hypertension"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1042\/CS20060247","volume":"112","author":"Savoia C.","year":"2007","unstructured":"Savoia C.; Schiffrin E.L.; Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 2007,112(7),375-384","journal-title":"Clin Sci (Lond)"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1161\/HYPERTENSIONAHA.111.187021","volume":"59","author":"Schiffrin E.L.","year":"2012","unstructured":"Schiffrin E.L.; Vascular remodeling in hypertension: mechanisms and treatment. Hypertension 2012,59(2),367-374","journal-title":"Hypertension"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.cardiores.2007.02.008","volume":"74","author":"Ruiz-Ortega M.","year":"2007","unstructured":"Ruiz-Ortega M.; Rodr\u00edguez-Vita J.; Sanchez-Lopez E.; Carvajal G.; Egido J.; TGF-\u03b2 signaling in vascular fibrosis. Cardiovasc Res 2007,74(2),196-206","journal-title":"Cardiovasc Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"H938","DOI":"10.1152\/ajpheart.00707.2009","volume":"298","author":"Viel E.C.","year":"2010","unstructured":"Viel E.C.; Lemari\u00e9 C.A.; Benkirane K.; Paradis P.; Schiffrin E.L.; Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol 2010,298(3),H938-H944","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"10C","DOI":"10.1016\/S0002-9149(01)01507-7","volume":"87","author":"Williams B.","year":"2001","unstructured":"Williams B.; Angiotensin II and the pathophysiology of cardiovascular remodeling. Am J Cardiol 2001,87(8A),10C-17C","journal-title":"Am J Cardiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1161\/hy0202.104270","volume":"39","author":"Abramson J.L.","year":"2002","unstructured":"Abramson J.L.; Weintraub W.S.; Vaccarino V.; Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002,39(2),197-202","journal-title":"Hypertension"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/00004872-200105000-00004","volume":"19","author":"Bautista L.E.","year":"2001","unstructured":"Bautista L.E.; L\u00f3pez-Jaramillo P.; Vera L.M.; Casas J.P.; Otero A.P.; Guaracao A.I.; Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001,19(5),857-861","journal-title":"J Hypertens"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1161\/01.CIR.0000104566.10178.AF","volume":"108","author":"Blake G.J.","year":"2003","unstructured":"Blake G.J.; Rifai N.; Buring J.E.; Ridker P.M.; Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003,108(24),2993-2999","journal-title":"Circulation"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1210\/jcem.86.3.7305","volume":"86","author":"Fernandez-Real J-M.","year":"2001","unstructured":"Fernandez-Real J-M.; Vayreda M.; Richart C.; Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab 2001,86(3),1154-1159","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13679-015-0169-4","volume":"4","author":"Williams E.P.","year":"2015","unstructured":"Williams E.P.; Mesidor M.; Winters K.; Dubbert P.M.; Wyatt S.B.; Overweight and obesity: Prevalence, consequences, and causes of a growing public health problem. Curr Obes Rep 2015,4(3),363-370","journal-title":"Curr Obes Rep"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/ijmr.IJMR_1768_17","volume":"151","author":"Mayoral L.P.","year":"2020","unstructured":"Mayoral L.P.; Andrade G.M.; Mayoral E.P.; Obesity subtypes, related biomarkers","journal-title":"Indian J Med Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11883-016-0575-4","volume":"18","author":"Mandviwala T.","year":"2016","unstructured":"Mandviwala T.; Khalid U.; Deswal A.; Obesity and cardiovascular disease: A risk factor or a risk marker? Curr Atheroscler Rep 2016,18(5),21","journal-title":"Curr Atheroscler Rep"},{"key":"ref=40","author":"Weir C.B.","year":"2021","unstructured":"Weir C.B.; Jan A.;  BMI Classification percentile and cut off points 2021","journal-title":"BMI Classification percentile and cut off points"},{"key":"ref=41","first-page":"s176","volume":"22","author":"Apovian C.M.","year":"2016","unstructured":"Apovian C.M.; Obesity: Definition, comorbidities, causes, and burden. Am J Manag Care 2016,22(7)(Suppl.),s176-s185","journal-title":"Am J Manag Care"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"139239","DOI":"10.1155\/2013\/139239","volume":"2013","author":"Makki K.","year":"2013","unstructured":"Makki K.; Froguel P.; Wolowczuk I.; Adipose tissue in obesity-related inflammation and insulin resistance: Cells, cytokines, and chemo-kines. ISRN Inflamm 2013,2013,139239","journal-title":"ISRN Inflamm"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/978-3-319-48382-5_15","volume":"960","author":"Engin A.","year":"2017","unstructured":"Engin A.;  Berlim: Springer 2017,960,345-379","journal-title":"Berlim: Springer"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"7711","DOI":"10.3390\/ijms21207711","volume":"21","author":"Feij\u00f3o-Band\u00edn S.","year":"2020","unstructured":"Feij\u00f3o-Band\u00edn S.; Arag\u00f3n-Herrera A.; Mora\u00f1a-Fern\u00e1ndez S.; Adipokines and inflammation: Focus on cardiovascular diseases. Int J Mol Sci 2020,21(20),7711","journal-title":"Int J Mol Sci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nature05487","volume":"444","author":"Van Gaal L.F.","year":"2006","unstructured":"Van Gaal L.F.; Mertens I.L.; De Block C.E.; Mechanisms linking obesity with cardiovascular disease. Nature 2006,444(7121),875-880","journal-title":"Nature"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3389\/fendo.2014.00204","volume":"5","author":"Ota T.","year":"2014","unstructured":"Ota T.; Obesity-induced inflammation and insulin resistance. Front Endocrinol (Lausanne) 2014,5,204","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12929-016-0303-y","volume":"23","author":"Rehman K.","year":"2016","unstructured":"Rehman K.; Akash M.S.H.; Mechanisms of inflammatory responses and development of insulin resistance: How are they interlinked? J Biomed Sci 2016,23(1),87","journal-title":"J Biomed Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"Vandanmagsar B.","year":"2011","unstructured":"Vandanmagsar B.; Youm Y-H.; Ravussin A.; The NLRP3 inflammasome instigates obesity-induced inflammation and insulin re-sistance. Nat Med 2011,17(2),179-188","journal-title":"Nat Med"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","volume":"10","author":"Zatterale F.","year":"2020","unstructured":"Zatterale F.; Longo M.; Naderi J.; Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes. Front Physiol 2020,10,1607","journal-title":"Front Physiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mam.2011.10.011","volume":"33","author":"Kalupahana N.S.","year":"2012","unstructured":"Kalupahana N.S.; Moustaid-Moussa N.; Claycombe K.J.; Immunity as a link between obesity and insulin resistance. Mol Aspects Med 2012,33(1),26-34","journal-title":"Mol Aspects Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1146\/annurev.physiol.70.113006.100707","volume":"70","author":"Myers M.G.","year":"2008","unstructured":"Myers M.G.; Cowley M.A.; M\u00fcnzberg H.; Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008,70(1),537-556","journal-title":"Annu Rev Physiol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4093\/dmj.2016.40.4.272","volume":"40","author":"Han C.Y.","year":"2016","unstructured":"Han C.Y.; Roles of reactive oxygen species on insulin resistance in adipose tissue. Diabetes Metab J 2016,40(4),272-279","journal-title":"Diabetes Metab J"},{"key":"ref=53","first-page":"502","volume":"21","author":"Li X.","year":"2018","unstructured":"Li X.; Endoplasmic reticulum stress regulates inflammation in adipocyte of obese rats via toll-like receptors 4 signaling. Iran J Basic Med Sci 2018,21(5),502-507","journal-title":"Iran J Basic Med Sci"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-319-48382-5_12","volume":"960","author":"Yaz\u0131c\u0131 D.","year":"2017","unstructured":"Yaz\u0131c\u0131 D.; Sezer H.; Insulin resistance obesity and lipotoxicity. Adv Exp Med Biol 2017,960,277-304","journal-title":"Adv Exp Med Biol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/157339908784220732","volume":"4","author":"Peppa M.","year":"2008","unstructured":"Peppa M.; Raptis S.A.; Advanced glycation end products and cardiovascular disease. Curr Diabetes Rev 2008,4(2),92-100","journal-title":"Curr Diabetes Rev"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/0003319720916301","volume":"71","author":"Yubero-Serrano E.M.","year":"2020","unstructured":"Yubero-Serrano E.M.; P\u00e9rez-Mart\u00ednez P.; Advanced glycation end products and their involvement in cardiovascular disease. Angiology 2020,71(8),698-700","journal-title":"Angiology"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1016\/j.febslet.2006.04.028","volume":"580","author":"Matsuzawa Y.","year":"2006","unstructured":"Matsuzawa Y.; The metabolic syndrome and adipocytokines. FEBS Lett 2006,580(12),2917-2921","journal-title":"FEBS Lett"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"942","DOI":"10.2337\/diabetes.52.4.942","volume":"52","author":"Engeli S.","year":"2003","unstructured":"Engeli S.; Feldpausch M.; Gorzelniak K.; Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003,52(4),942-947","journal-title":"Diabetes"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1210\/jc.2004-0395","volume":"89","author":"Kershaw E.E.","year":"2004","unstructured":"Kershaw E.E.; Flier J.S.; Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004,89(6),2548-2556","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.biopha.2017.10.021","volume":"96","author":"Jang S-A.","year":"2017","unstructured":"Jang S-A.; Park D.W.; Kwon J.E.; Quinic acid inhibits vascular inflammation in TNF-\u03b1-stimulated vascular smooth muscle cells. Biomed Pharmacother 2017,96,563-571","journal-title":"Biomed Pharmacother"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2213-8587(14)70134-2","volume":"3","author":"Cox A.J.","year":"2015","unstructured":"Cox A.J.; West N.P.; Cripps A.W.; Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol 2015,3(3),207-215","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"E414","DOI":"10.1152\/ajpendo.00418.2014","volume":"308","author":"Chen S.","year":"2015","unstructured":"Chen S.; Okahara F.; Osaki N.; Shimotoyodome A.; Increased GIP signaling induces adipose inflammation via a HIF-1\u03b1-dependent pathway and impairs insulin sensitivity in mice. Am J Physiol Endocrinol Metab 2015,308(5),E414-E425","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1177\/2047487319891783","volume":"27","author":"Janssen A.","year":"2020","unstructured":"Janssen A.; Grobbee D.E.; Dendale P.; Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease. Eur J Prev Cardiol 2020,27(10),1059-1063","journal-title":"Eur J Prev Cardiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"Byrne C.D.","year":"2015","unstructured":"Byrne C.D.; Targher G.; NAFLD: A multisystem disease. J Hepatol 2015,62(1)(Suppl.),S47-S64","journal-title":"J Hepatol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","volume":"142","author":"Cusi K.","year":"2012","unstructured":"Cusi K.; Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. Gastroenterology 2012,142(4),711-725","journal-title":"Gastroenterology"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/labinvest.2014.3","volume":"94","author":"Dorn C.","year":"2014","unstructured":"Dorn C.; Engelmann J.C.; Saugspier M.; Increased expression of c-Jun in nonalcoholic fatty liver disease. Lab Invest 2014,94(4),394-408","journal-title":"Lab Invest"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"Kasper P.","year":"2021","unstructured":"Kasper P.; Martin A.; Lang S.; NAFLD and cardiovascular diseases: A clinical review. Clin Res Cardiol 2021,110(7),921-937","journal-title":"Clin Res Cardiol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fcvm.2020.00022","volume":"7","author":"Chait A.","year":"2020","unstructured":"Chait A.; den Hartigh L.J.; Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front Cardiovasc Med 2020,7,22","journal-title":"Front Cardiovasc Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3132\/dvdr.2007.025","volume":"4","author":"Hartge M.M.","year":"2007","unstructured":"Hartge M.M.; Unger T.; Kintscher U.; The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res 2007,4(2),84-88","journal-title":"Diab Vasc Dis Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/S0140-6736(09)60874-6","volume":"373","author":"Dabelea D.","year":"2009","unstructured":"Dabelea D.; The accelerating epidemic of childhood diabetes. Lancet 2009,373(9680),1999-2000","journal-title":"Lancet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"h3576","DOI":"10.1136\/bmj.h3576","volume":"351","author":"Imamura F.","year":"2015","unstructured":"Imamura F.; O\u2019Connor L.; Ye Z.; Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. BMJ 2015,351,h3576","journal-title":"BMJ"},{"key":"ref=72","year":"2021","unstructured":"Diabetes World Health Organization2021","journal-title":"Diabetes"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"583687","DOI":"10.3389\/fimmu.2020.583687","volume":"11","author":"Forrester J.V.","year":"2020","unstructured":"Forrester J.V.; Kuffova L.; Delibegovic M.; The Role of inflammation in diabetic retinopathy. Front Immunol 2020,11,583687","journal-title":"Front Immunol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"9524635","DOI":"10.1155\/2020\/9524635","volume":"2020","author":"Pang L.","year":"2020","unstructured":"Pang L.; Lian X.; Liu H.; Understanding diabetic neuropathy: Focus on oxidative stress. Oxid Med Cell Longev 2020,2020,9524635","journal-title":"Oxid Med Cell Longev"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","volume":"62","author":"Braunwald E.","year":"2019","unstructured":"Braunwald E.; Diabetes, heart failure, and renal dysfunction: The vicious circles. Prog Cardiovasc Dis 2019,62(4),298-302","journal-title":"Prog Cardiovasc Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2217\/fca-2018-0045","volume":"14","author":"Henning R.J.","year":"2018","unstructured":"Henning R.J.; Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol 2018,14(6),491-509","journal-title":"Future Cardiol"},{"key":"ref=77","doi-asserted-by":"publisher","author":"Dal Canto E","unstructured":"Dal Canto E; Ceriello A; Ryd\u00e9n L;  Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019; 26(2_suppl)(Suppl.): 25-32.","DOI":"10.1177\/2047487319878371"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"129","DOI":"10.13105\/wjma.v7.i4.129","volume":"7","author":"Xourgia E.","year":"2019","unstructured":"Xourgia E.; Tzouganatou E-M.; Papazafeiropoulou A.; Anti-inflammatory properties of antidiabetic agents. World J Metaanal 2019,7(4),129-141","journal-title":"World J Metaanal"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"A1830","DOI":"10.1016\/S0735-1097(18)32371-4","volume":"71","author":"Tan S.A.","year":"2018","unstructured":"Tan S.A.; Tan L.; Empagliflozin and canagliflozin attenuate inflammatory cytokines interferon-\u03b3, tumor necrosis factor-\u03b1, interleukin-6: Possible mechanism of decreasing cardiovascular risk in diabetes mellitus. J Am Coll Cardiol 2018,71(11),A1830","journal-title":"J Am Coll Cardiol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"Xu L.","year":"2017","unstructured":"Xu L.; Nagata N.; Nagashimada M.; SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflamma-tion and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine 2017,20,137-149","journal-title":"EBioMedicine"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Neal B.","year":"2017","unstructured":"Neal B.; Perkovic V.; Mahaffey K.W.; Canagliflozin and cardiovascular and renal events in type 2 Diabetes. N Engl J Med 2017,377(7),644-657","journal-title":"N Engl J Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"Wiviott S.D.","year":"2019","unstructured":"Wiviott S.D.; Raz I.; Bonaca M.P.; Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019,380(4),347-357","journal-title":"N Engl J Med"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"Perkovic V.","year":"2019","unstructured":"Perkovic V.; Jardine M.J.; Neal B.; Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019,380(24),2295-2306","journal-title":"N Engl J Med"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"Drucker D.J.","year":"2006","unstructured":"Drucker D.J.; Nauck M.A.; The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006,368(9548),1696-1705","journal-title":"Lancet"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jcjd.2014.01.008","volume":"38","author":"Yang L.","year":"2014","unstructured":"Yang L.; Yuan J.; Zhou Z.; Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus. Can J Diabetes 2014,38(6),473-479","journal-title":"Can J Diabetes"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"Marso S.P.","year":"2016","unstructured":"Marso S.P.; Daniels G.H.; Brown-Frandsen K.; Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016,375(4),311-322","journal-title":"N Engl J Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"Marso S.P.","year":"2016","unstructured":"Marso S.P.; Bain S.C.; Consoli A.; Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016,375(19),1834-1844","journal-title":"N Engl J Med"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2337\/ds16-0026","volume":"30","author":"Hinnen D.","year":"2017","unstructured":"Hinnen D.; Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr 2017,30(3),202-210","journal-title":"Diabetes Spectr"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"Holman R.R.","year":"2017","unstructured":"Holman R.R.; Bethel M.A.; Mentz R.J.; Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017,377(13),1228-1239","journal-title":"N Engl J Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"Rosenstock J.","year":"2019","unstructured":"Rosenstock J.; Perkovic V.; Johansen O.E.; Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabe-tes and high cardiovascular and renal risk. JAMA 2019,321(1),69-79","journal-title":"JAMA"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.2337\/db09-1694","volume":"59","author":"Arakawa M.","year":"2010","unstructured":"Arakawa M.; Mita T.; Azuma K.; Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010,59(4),1030-1037","journal-title":"Diabetes"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00210-016-1277-8","volume":"389","author":"Bu\u0142dak \u0141.","year":"2016","unstructured":"Bu\u0142dak \u0141.; Machnik G.; Bu\u0142dak R.J.; \u0141abuzek K.; Bo\u0142dys A.; Okopie\u0144 B.; Exenatide and metformin express their anti-inflammatory effects on human monocytes\/macrophages by the attenuation of MAPKs and NF\u03baB signaling. Naunyn Schmiedebergs Arch Pharmacol 2016,389(10),1103-1115","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.2337\/dc12-0199","volume":"35","author":"Rizzo M.R.","year":"2012","unstructured":"Rizzo M.R.; Barbieri M.; Marfella R.; Paolisso G.; Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012,35(10),2076-2082","journal-title":"Diabetes Care"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/1047-2797(92)90033-M","volume":"2","author":"Castelli W.P.","year":"1992","unstructured":"Castelli W.P.; Anderson K.; Wilson P.W.F.; Levy D.; Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992,2(1-2),23-28","journal-title":"Ann Epidemiol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0002-9343(86)90157-9","volume":"80","author":"Castelli W.P.","year":"1986","unstructured":"Castelli W.P.; Anderson K.; A population at risk. Prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med 1986,80(2A),23-32","journal-title":"Am J Med"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","volume":"388","author":"Collins R.","year":"2016","unstructured":"Collins R.; Reith C.; Emberson J.; Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016,388(10059),2532-2561","journal-title":"Lancet"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"Shepherd J.","year":"1995","unstructured":"Shepherd J.; Cobbe S.M.; Ford I.; Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995,333(20),1301-1307","journal-title":"N Engl J Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0002-9149(97)00347-0","volume":"80","author":"Downs J.R.","year":"1997","unstructured":"Downs J.R.; Beere P.A.; Whitney E.; Design","journal-title":"Am J Cardiol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"Cannon C.P.","year":"2004","unstructured":"Cannon C.P.; Braunwald E.; McCabe C.H.; Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004,350(15),1495-1504","journal-title":"N Engl J Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"LaRosa J.C.","year":"2005","unstructured":"LaRosa J.C.; Grundy S.M.; Waters D.D.; Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005,352(14),1425-1435","journal-title":"N Engl J Med"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"Ridker P.M.","year":"2008","unstructured":"Ridker P.M.; Danielson E.; Fonseca F.A.H.; Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008,359(21),2195-2207","journal-title":"N Engl J Med"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"Nissen S.E.","year":"2004","unstructured":"Nissen S.E.; Tuzcu E.M.; Schoenhagen P.; Effect of intensive compared with moderate lipid-lowering therapy on progression of coro-nary atherosclerosis: A randomized controlled trial. JAMA 2004,291(9),1071-1080","journal-title":"JAMA"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2217\/14796678.2.6.651","volume":"2","author":"Chhatriwalla A.K.","year":"2006","unstructured":"Chhatriwalla A.K.; Nicholls S.J.; Nissen S.E.; The ASTEROID trial: Coronary plaque regression with high-dose statin therapy. Future Cardiol 2006,2(6),651-654","journal-title":"Future Cardiol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1185\/03007995.2011.570746","volume":"27","author":"Nicholls S.J.","year":"2011","unstructured":"Nicholls S.J.; Borgman M.; Nissen S.E.; Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Curr Med Res Opin 2011,27(6),1119-1129","journal-title":"Curr Med Res Opin"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.jacl.2017.05.001","volume":"11","author":"Orringer C.E.","year":"2017","unstructured":"Orringer C.E.; Jacobson T.A.; Saseen J.J.; Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol 2017,11(4),880-890","journal-title":"J Clin Lipidol"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/14712598.2020.1677604","volume":"20","author":"Steffens D.","year":"2020","unstructured":"Steffens D.; Bramlage P.; Scheeff C.; PCSK9 inhibitors and cardiovascular outcomes. Expert Opin Biol Ther 2020,20(1),35-47","journal-title":"Expert Opin Biol Ther"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"H317","DOI":"10.1152\/ajpheart.00182.2013","volume":"306","author":"Xiao L.","year":"2014","unstructured":"Xiao L.; Liu Y.; Wang N.; New paradigms in inflammatory signaling in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2014,306(3),H317-H325","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/0167-5699(94)90137-6","volume":"15","author":"Baumann H.","year":"1994","unstructured":"Baumann H.; Gauldie J.; The acute phase response. Immunol Today 1994,15(2),74-80","journal-title":"Immunol Today"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1053\/euhj.1999.2207","volume":"21","author":"Woods A.","year":"2000","unstructured":"Woods A.; Brull D.J.; Humphries S.E.; Montgomery H.E.; Genetics of inflammation and risk of coronary artery disease: The central role of interleukin-6. Eur Heart J 2000,21(19),1574-1583","journal-title":"Eur Heart J"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","volume":"107","author":"Pearson T.A.","year":"2003","unstructured":"Pearson T.A.; Mensah G.A.; Alexander R.W.; Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart As-sociation. Circulation 2003,107(3),499-511","journal-title":"Circulation"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/01.CIR.0000053730.47739.3C","volume":"107","author":"Ridker P.M.","year":"2003","unstructured":"Ridker P.M.; Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003,107(3),363-369","journal-title":"Circulation"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.bcp.2009.04.029","volume":"78","author":"Sprague A.H.","year":"2009","unstructured":"Sprague A.H.; Khalil R.A.; Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009,78(6),539-552","journal-title":"Biochem Pharmacol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1161\/01.CIR.0000089190.95415.9F","volume":"108","author":"Szmitko P.E.","year":"2003","unstructured":"Szmitko P.E.; Wang C-H.; Weisel R.D.; de Almeida J.R.; Anderson T.J.; Verma S.; New markers of inflammation and endothelial cell activation: Part I. Circulation 2003,108(16),1917-1923","journal-title":"Circulation"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"222","DOI":"10.5830\/CVJA-2011-068","volume":"23","author":"Mudau M.","year":"2012","unstructured":"Mudau M.; Genis A.; Lochner A.; Strijdom H.; Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J S Afr 2012,23(4),222-231","journal-title":"Cardiovasc J S Afr"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"71B","DOI":"10.1016\/0002-9149(95)80017-M","volume":"75","author":"Anderson T.J.","year":"1995","unstructured":"Anderson T.J.; Gerhard M.D.; Meredith I.T.; Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol 1995,75(6),71B-74B","journal-title":"Am J Cardiol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vph.2017.05.005","volume":"100","author":"Incalza M.A.","year":"2018","unstructured":"Incalza M.A.; D\u2019Oria R.; Natalicchio A.; Perrini S.; Laviola L.; Giorgino F.; Oxidative stress and reactive oxygen species in endothelial dys-function associated with cardiovascular and metabolic diseases. Vascul Pharmacol 2018,100,1-19","journal-title":"Vascul Pharmacol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bjp.0703393","volume":"130","author":"De Vriese A.S.","year":"2000","unstructured":"De Vriese A.S.; Verbeuren T.J.; Van de Voorde J.; Lameire N.H.; Vanhoutte P.M.; Endothelial dysfunction in diabetes. Br J Pharmacol 2000,130(5),963-974","journal-title":"Br J Pharmacol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1055\/s-2000-13209","volume":"26","author":"Landmesser U.","year":"2000","unstructured":"Landmesser U.; Hornig B.; Drexler H.; Endothelial dysfunction in hypercholesterolemia: Mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost 2000,26(5),529-537","journal-title":"Semin Thromb Hemost"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2174\/1573399052952550","volume":"1","author":"Nakagami H.","year":"2005","unstructured":"Nakagami H.; Kaneda Y.; Ogihara T.; Morishita R.; Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. Curr Diabetes Rev 2005,1(1),59-63","journal-title":"Curr Diabetes Rev"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1161\/ATVBAHA.113.300156","volume":"34","author":"Messner B.","year":"2014","unstructured":"Messner B.; Bernhard D.; Smoking and cardiovascular disease: Mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 2014,34(3),509-515","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2143\/AC.55.4.2005744","volume":"55","author":"Puddu P.","year":"2000","unstructured":"Puddu P.; Puddu G.M.; Zaca F.; Muscari A.; Endothelial dysfunction in hypertension. Acta Cardiol 2000,55(4),221-232","journal-title":"Acta Cardiol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","volume":"39","author":"Ridker P.M.","year":"2018","unstructured":"Ridker P.M.; Libby P.; MacFadyen J.G.; Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J 2018,39(38),3499-3507","journal-title":"Eur Heart J"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1258\/cvd.2012.012024","volume":"1","author":"Quinn U.","year":"2012","unstructured":"Quinn U.; Tomlinson L.A.; Cockcroft J.R.; Arterial stiffness. JRSM Cardiovasc Dis 2012,1(6),1-8","journal-title":"JRSM Cardiovasc Dis"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1093\/eurheartj\/ehl254","volume":"27","author":"Laurent S.","year":"2006","unstructured":"Laurent S.; Cockcroft J.; Van Bortel L.; Expert consensus document on arterial stiffness: methodological issues and clinical applica-tions. Eur Heart J 2006,27(21),2588-2605","journal-title":"Eur Heart J"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1161\/01.HYP.37.5.1236","volume":"37","author":"Laurent S.","year":"2001","unstructured":"Laurent S.; Boutouyrie P.; Asmar R.; Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hyperten-sive patients. Hypertension 2001,37(5),1236-1241","journal-title":"Hypertension"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3389\/fimmu.2017.01058","volume":"8","author":"Mozos I.","year":"2017","unstructured":"Mozos I.; Malainer C.; Horba\u0144czuk J.; Inflammatory markers for arterial stiffness in cardiovascular diseases. Front Immunol 2017,8,1058","journal-title":"Front Immunol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1161\/01.HYP.0000168055.89955.db","volume":"46","author":"Roman M.J.","year":"2005","unstructured":"Roman M.J.; Devereux R.B.; Schwartz J.E.; Arterial stiffness in chronic inflammatory diseases. Hypertension 2005,46(1),194-199","journal-title":"Hypertension"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1161\/01.HYP.0000185463.27209.b0","volume":"46","author":"Mahmud A.","year":"2005","unstructured":"Mahmud A.; Feely J.; Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005,46(5),1118-1122","journal-title":"Hypertension"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1113\/JP270033","volume":"593","author":"Wang G.","year":"2015","unstructured":"Wang G.; Jacquet L.; Karamariti E.; Xu Q.; Origin and differentiation of vascular smooth muscle cells. J Physiol 2015,593(14),3013-3030","journal-title":"J Physiol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/cvr\/cvy022","volume":"114","author":"Allahverdian S.","year":"2018","unstructured":"Allahverdian S.; Chaabane C.; Boukais K.; Francis G.A.; Bochaton-Piallat M.L.; Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc Res 2018,114(4),540-550","journal-title":"Cardiovasc Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"20130852","DOI":"10.1098\/rsif.2013.0852","volume":"11","author":"Qiu J.","year":"2013","unstructured":"Qiu J.; Zheng Y.; Hu J.; Biomechanical regulation of vascular smooth muscle cell functions: from in vitro to in vivo understanding. J R Soc Interface 2013,11(90),20130852","journal-title":"J R Soc Interface"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1097\/HJH.0000000000002508","volume":"38","author":"Zanoli L.","year":"2020","unstructured":"Zanoli L.; Briet M.; Empana J.P.; Vascular consequences of inflammation: A position statement from the ESH working group on vascu-lar structure and function and the ARTERY Society. J Hypertens 2020,38(9),1682-1698","journal-title":"J Hypertens"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1161\/HYPERTENSIONAHA.115.06262","volume":"67","author":"Bersi M.R.","year":"2016","unstructured":"Bersi M.R.; Bellini C.; Wu J.; Montaniel K.R.C.; Harrison D.G.; Humphrey J.D.; Excessive adventitial remodeling leads to early aortic maladapta-tion in angiotensin-induced hypertension. Hypertension 2016,67(5),890-896","journal-title":"Hypertension"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.cardiores.2007.06.023","volume":"75","author":"Maiellaro K.","year":"2007","unstructured":"Maiellaro K.; Taylor W.R.; The role of the adventitia in vascular inflammation. Cardiovasc Res 2007,75(4),640-648","journal-title":"Cardiovasc Res"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/01.ATV.zhq0504.0173","volume":"24","author":"Yasmin McEniery C.M.","year":"2004","unstructured":"Yasmin McEniery C.M.; Wallace S.; C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004,24(5),969-974","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/art.10748","volume":"48","author":"Wong M.","year":"2003","unstructured":"Wong M.; Toh L.; Wilson A.; Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum 2003,48(1),81-89","journal-title":"Arthritis Rheum"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.20002","volume":"50","author":"Booth A.D.","year":"2004","unstructured":"Booth A.D.; Wallace S.; McEniery C.M.; Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 2004,50(2),581-588","journal-title":"Arthritis Rheum"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2020.01.028","volume":"297","author":"Mendoza-Pinto C.","year":"2020","unstructured":"Mendoza-Pinto C.; Rojas-Villarraga A.; Molano-Gonz\u00e1lez N.; Endothelial dysfunction and arterial stiffness in patients with systemic lupus erythematosus: A systematic review and meta-analysis. Atherosclerosis 2020,297,55-63","journal-title":"Atherosclerosis"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1161\/01.CIR.0000037521.71373.44","volume":"106","author":"H\u00fcrlimann D.","year":"2002","unstructured":"H\u00fcrlimann D.; Forster A.; Noll G.; Anti-tumor necrosis factor-\u03b1 treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002,106(17),2184-2187","journal-title":"Circulation"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.105.601641","volume":"114","author":"M\u00e4ki-Pet\u00e4j\u00e4 K.M.","year":"2006","unstructured":"M\u00e4ki-Pet\u00e4j\u00e4 K.M.; Hall F.C.; Booth A.D.; Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-\u03b1 therapy. Circulation 2006,114(11),1185-1192","journal-title":"Circulation"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","volume":"101","author":"Ridker P.M.","year":"2000","unstructured":"Ridker P.M.; Rifai N.; Stampfer M.J.; Hennekens C.H.; Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000,101(15),1767-1772","journal-title":"Circulation"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","volume":"140","author":"Takeuchi O.","year":"2010","unstructured":"Takeuchi O.; Akira S.; Pattern recognition receptors and inflammation. Cell 2010,140(6),805-820","journal-title":"Cell"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"e86903","DOI":"10.1371\/journal.pone.0086903","volume":"9","author":"Sessa L.","year":"2014","unstructured":"Sessa L.; Gatti E.; Zeni F.; The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs). PLoS One 2014,9(1),e86903","journal-title":"PLoS One"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10522-019-09808-3","volume":"20","author":"Teissier T.","year":"2019","unstructured":"Teissier T.; Boulanger \u00c9.; The receptor for advanced glycation end-products (RAGE) is an important pattern recognition receptor (PRR) for inflammaging. Biogerontology 2019,20(3),279-301","journal-title":"Biogerontology"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","volume":"20","author":"Gong T.","year":"2020","unstructured":"Gong T.; Liu L.; Jiang W.; Zhou R.; DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 2020,20(2),95-112","journal-title":"Nat Rev Immunol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"e3074","DOI":"10.1038\/cddis.2017.470","volume":"8","author":"Sun H-J.","year":"2017","unstructured":"Sun H-J.; Ren X-S.; Xiong X-Q.; NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension. Cell Death Dis 2017,8(10),e3074-e4","journal-title":"Cell Death Dis"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","volume":"157","author":"Lamkanfi M.","year":"2014","unstructured":"Lamkanfi M.; Dixit V.M.; Mechanisms and functions of inflammasomes. Cell 2014,157(5),1013-1022","journal-title":"Cell"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"Martinon F.","year":"2002","unstructured":"Martinon F.; Burns K.; Tschopp J.; The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002,10(2),417-426","journal-title":"Mol Cell"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41419-020-02985-x","volume":"11","author":"Bai B.","year":"2020","unstructured":"Bai B.; Yang Y.; Wang Q.; NLRP3 inflammasome in endothelial dysfunction. Cell Death Dis 2020,11(9),776","journal-title":"Cell Death Dis"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","volume":"122","author":"Grebe A.","year":"2018","unstructured":"Grebe A.; Hoss F.; Latz E.; NLRP3 inflammasome and the IL-1 pathway in atherosclerosis. Circ Res 2018,122(12),1722-1740","journal-title":"Circ Res"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","volume":"70","author":"Libby P.","year":"2017","unstructured":"Libby P.; Interleukin-1 beta as a target for atherosclerosis therapy. J Am Coll Cardiol 2017,70(18),2278-2289","journal-title":"J Am Coll Cardiol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10875-007-9104-0","volume":"27","author":"Chun H-Y.","year":"2007","unstructured":"Chun H-Y.; Chung J-W.; Kim H-A.; Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007,27(5),461-466","journal-title":"J Clin Immunol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2174\/1570161118666191227101636","volume":"18","author":"Kostopoulou M.","year":"2020","unstructured":"Kostopoulou M.; Nikolopoulos D.; Parodis I.; Bertsias G.; Cardiovascular disease in systemic lupus erythematosus: recent data on epidemi-ology, risk factors and prevention. Curr Vasc Pharmacol 2020,18(6),549-565","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"566","DOI":"10.2174\/1570161118666200127142936","volume":"18","author":"Atzeni F.","year":"2020","unstructured":"Atzeni F.; Nucera V.; Gerratana E.; Cardiovascular consequences of autoimmune rheumatic diseases. Curr Vasc Pharmacol 2020,18(6),566-579","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar1916","volume":"8","author":"Kishimoto T.","year":"2006","unstructured":"Kishimoto T.; Interleukin-6: Discovery of a pleiotropic cytokine. Arthritis Res Ther 2006,8(Suppl. 2),S2","journal-title":"Arthritis Res Ther"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"e0233811","DOI":"10.1371\/journal.pone.0233811","volume":"15","author":"Mavropoulou E.","year":"2020","unstructured":"Mavropoulou E.; Mechie N-C.; Knoop R.; Association of serum interleukin-6 and soluble interleukin-2-receptor levels with disease activity status in patients with inflammatory bowel disease: A prospective observational study. PLoS One 2020,15(5),e0233811","journal-title":"PLoS One"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ijcard.2021.04.062","volume":"337","author":"Ulander L.","year":"2021","unstructured":"Ulander L.; Tolppanen H.; Hartman O.; Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial. Int J Cardiol 2021,337,21-27","journal-title":"Int J Cardiol"},{"key":"ref=159","first-page":"92","volume":"3","author":"Hartman O.","year":"2017","unstructured":"Hartman O.; Kovanen P.T.; Lehtonen J.; Eklund K.K.; Sinisalo J.; Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. Eur Heart J Cardiovasc Pharmacother 2017,3(2),92-97","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3389\/fcvm.2017.00084","volume":"4","author":"Akita K.","year":"2017","unstructured":"Akita K.; Isoda K.; Sato-Okabayashi Y.; An interleukin-6 receptor antibody suppresses atherosclerosis in atherogenic mice. Front Cardiovasc Med 2017,4,84","journal-title":"Front Cardiovasc Med"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11883-020-0819-1","volume":"22","author":"Biondi-Zoccai G.","year":"2020","unstructured":"Biondi-Zoccai G.; Garmendia C.M.; Abbate A.; Atherothrombosis prevention and treatment with anti-interleukin-1 agents. Curr Atheroscler Rep 2020,22(1),4","journal-title":"Curr Atheroscler Rep"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40259-018-0274-5","volume":"32","author":"Buckley L.F.","year":"2018","unstructured":"Buckley L.F.; Abbate A.; Interleukin-1 blockade in cardiovascular diseases: from bench to bedside. BioDrugs 2018,32(2),111-118","journal-title":"BioDrugs"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"173822","DOI":"10.1016\/j.ejphar.2020.173822","volume":"893","author":"Luo P.","year":"2021","unstructured":"Luo P.; Wang Y.; Zhao C.; Bazedoxifene exhibits anti-inflammation and anti-atherosclerotic effects via inhibition of IL-6\/IL-6R\/STAT3 signaling. Eur J Pharmacol 2021,893,173822","journal-title":"Eur J Pharmacol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"e012241","DOI":"10.1161\/JAHA.119.012241","volume":"8","author":"Alonso A.","year":"2019","unstructured":"Alonso A.; Barnes A.E.; Guest J.L.; Shah A.; Shao I.Y.; Marconi V.; HIV infection and incidence of cardiovascular diseases: An analysis of a large healthcare database. J Am Heart Assoc 2019,8(14),e012241","journal-title":"J Am Heart Assoc"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1161\/01.ATV.0000021412.56621.A2","volume":"22","author":"Brasier A.R.","year":"2002","unstructured":"Brasier A.R.; Recinos A.; Eledrisi M.S.; Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002,22(8),1257-1266","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/sj.jhh.1002101","volume":"21","author":"Dandona P.","year":"2007","unstructured":"Dandona P.; Dhindsa S.; Ghanim H.; Chaudhuri A.; Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007,21(1),20-27","journal-title":"J Hum Hypertens"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.atherosclerosis.2014.05.398","volume":"235","author":"Lindeman J.H.N.","year":"2014","unstructured":"Lindeman J.H.N.; Ace inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm. Atherosclerosis 2014,235(2),e141","journal-title":"Atherosclerosis"},{"key":"ref=168","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/01.HYP.0000226046.58883.32","volume":"48","author":"Ridker P.M.","year":"2006","unstructured":"Ridker P.M.; Danielson E.; Rifai N.; Valsartan, blood pressure reduction, and C-reactive protein. Hypertension 2006,48(1),73-79","journal-title":"Hypertension"},{"key":"ref=169","author":"Mahwati Y","unstructured":"Mahwati Y; Nurrika D.;  Obesity Indicators and C-reactive protein in Indonesian adults (\u2265 40 years): The indonesian family life survey-5 2014-2015. Kesmas Natl Public Heal J 2020; 15(3)."},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1001\/jama.289.14.1799","volume":"289","author":"Esposito K.","year":"2003","unstructured":"Esposito K.; Pontillo A.; Di Palo C.; Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: A randomized trial. JAMA 2003,289(14),1799-1804","journal-title":"JAMA"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-019-0942-x","volume":"18","author":"Clegg L.E.","year":"2019","unstructured":"Clegg L.E.; Penland R.C.; Bachina S.; Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol 2019,18(1),138","journal-title":"Cardiovasc Diabetol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13098-020-00533-3","volume":"12","author":"Hattori S.","year":"2020","unstructured":"Hattori S.; Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes. Diabetol Metab Syndr 2020,12(1),24","journal-title":"Diabetol Metab Syndr"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","volume":"5","author":"Lopaschuk G.D.","year":"2020","unstructured":"Lopaschuk G.D.; Verma S.; Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. JACC Basic Transl Sci 2020,5(6),632-644","journal-title":"JACC Basic Transl Sci"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"McGuire D.K.","year":"2021","unstructured":"McGuire D.K.; Shih W.J.; Cosentino F.; Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. JAMA Cardiol 2021,6(2),148-158","journal-title":"JAMA Cardiol"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1073\/pnas.74.4.1729","volume":"74","author":"Phillips G.B.","year":"1977","unstructured":"Phillips G.B.; Relationship between serum sex hormones and glucose, insulin and lipid abnormalities in men with myocardial infarction. Proc Natl Acad Sci USA 1977,74(4),1729-1733","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","volume":"17","author":"Sposito A.C.","year":"2018","unstructured":"Sposito A.C.; Berwanger O.; de Carvalho L.S.F.; Saraiva J.F.K.; GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovasc Diabetol 2018,17(1),157","journal-title":"Cardiovasc Diabetol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"18185","DOI":"10.3390\/ijms160818185","volume":"16","author":"Steven S.","year":"2015","unstructured":"Steven S.; M\u00fcnzel T.; Daiber A.; Exploiting the pleiotropic antioxidant effects of established drugs in cardiovascular disease. Int J Mol Sci 2015,16(8),18185-18223","journal-title":"Int J Mol Sci"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"e18245","DOI":"10.1097\/MD.0000000000018245","volume":"98","author":"Zou C-Y.","year":"2019","unstructured":"Zou C-Y.; Liu X-K.; Sang Y-Q.; Wang B.; Liang J.; Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis. Medicine (Baltimore) 2019,98(49),e18245","journal-title":"Medicine (Baltimore)"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000100954","volume":"51","author":"Aksungar F.B.","year":"2007","unstructured":"Aksungar F.B.; Topkaya A.E.; Akyildiz M.; Interleukin-6, C-reactive protein and biochemical parameters during prolonged intermittent fasting. Ann Nutr Metab 2007,51(1),88-95","journal-title":"Ann Nutr Metab"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1080\/07315724.2017.1339644","volume":"36","author":"Aliasghari F.","year":"2017","unstructured":"Aliasghari F.; Izadi A.; Gargari B.P.; Ebrahimi S.; The effects of ramadan fasting on body composition, blood pressure, glucose] metabolism, and markers of inflammation in NAFLD patients: An observational trial. J Am Coll Nutr 2017,36(8),640-645","journal-title":"J Am Coll Nutr"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12967-018-1748-4","volume":"16","author":"Cioffi I.","year":"2018","unstructured":"Cioffi I.; Evangelista A.; Ponzo V.; Intermittent versus continuous energy restriction on weight loss and cardiometabolic outcomes: a systematic review and meta-analysis of randomized controlled trials. J Transl Med 2018,16(1),371","journal-title":"J Transl Med"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3390\/nu11030673","volume":"11","author":"Malinowski B.","year":"2019","unstructured":"Malinowski B.; Zalewska K.; W\u0119sierska A.; Intermittent fasting in cardiovascular disorders-an overview. Nutrients 2019,11(3),673","journal-title":"Nutrients"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11154-019-09524-w","volume":"21","author":"Pellegrini M.","year":"2020","unstructured":"Pellegrini M.; Cioffi I.; Evangelista A.; Effects of time-restricted feeding on body weight and metabolism. A systematic review and meta-analysis. Rev Endocr Metab Disord 2020,21(1),17-33","journal-title":"Rev Endocr Metab Disord"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","volume":"34","author":"Petrie J.R.","year":"2018","unstructured":"Petrie J.R.; Guzik T.J.; Touyz R.M.; Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. Can J Cardiol 2018,34(5),575-584","journal-title":"Can J Cardiol"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570161120666220201160038","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/200756\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570161120666220201160038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T18:32:27Z","timestamp":1691865147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/200756\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":184,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570161120666220201160038","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-07-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}